Therapeutic Potential of Melatonin, Erythropoietin, and TRPV4 Antagonism in a Preclinical Model of Genetic Hydrocephalus
Preprint
Abstract
Symptomatic hydrocephalus is a neuropathological disorder of cerebrospinal fluid (CSF) homeostasis characterized by abnormal accumulation of CSF and progressive ventricular enlargement. Current treatment relies primarily on surgical CSF diversion, which is invasive and associated with substantial rates of treatment failure and surgical revisions. Congenital hydrocephalus can be caused by genetic pathologies; for example, a point mutation in the Meckel-Gruber type 3, Tmem 67, gene produces a congenital hydrocephalus phenotype in rats, characterized by progressive ventriculomegaly. Here, we evaluated a combinatorial cocktail therapeutic strategy consisting of erythropoietin (EPO), melatonin (MLT), and the transient receptor potential vanilloid 4 (TRPV4) antagonist, RN1734 (RN), in the Tmem 67□□□ rat model of congenital hydrocephalus. Magnetic Resonance Imaging (MRI) demonstrated marked progression of ventriculomegaly in untreated Tmem 67□□□ rats between postnatal (P) 7 and P15. RN1734 and EPO+MLT+RN1734 (triple therapy) from P7-P14 prevented further ventricular expansion. Hydrocephalus is associated with structural disruption of the periventricular white matter (WM) and ependymal lining (EL), accompanied by regionally increased TLR4 and NLRP3-associated inflammatory signaling. EPO+MLT, RN1734, or triple therapy differentially attenuated these inflammatory responses. The triple combination reduced both TLR4 and NLRP3 protein abundance within the affected periventricular region and ameliorated the structural alterations. These findings support a combined therapeutic approach that addresses ventricular pathology, inflammation and periventricular structural consequences of congenital hydrocephalus.Keywords
This publication has 49 references indexed in Scilit:
- The TLR4/MyD88 axis: Orchestrator of neuroinflammation from molecular initiation to systemic crosstalkBrain Hemorrhages, 2026
- The Role of Choroid Plexus in Hydrocephalus from the Perspective of Structure and Function: a Therapeutic TargetMolecular Neurobiology, 2025
- Oxidative stress in hydrocephalus: A new potential therapeutic targetBrain‐X, 2024
- Hydrocephalus: An update on latest progress in pathophysiological and therapeutic researchBiomedicine & Pharmacotherapy, 2024
- Melatonin: A review of its potential functions and effects on neurological diseasesRevue Neurologique, 2020
- Erythropoietin: Emerging Role of Erythropoietin in Neonatal NeuroprotectionPediatric Neurology, 2014
- Pathophysiology of congenital and neonatal hydrocephalusSeminars in Fetal and Neonatal Medicine, 2012
- Erythropoietin promotes oligodendrogenesis and myelin repair following lysolecithin-induced injury in spinal cord slice cultureBiochemical and Biophysical Research Communications, 2012
- Role of melatonin receptors in the effects of melatonin on BDNF and neuroprotection in mouse cerebellar neuronsJournal of Neural Transmission, 2008
- Development of multiorgan pathology in the wpk rat model of polycystic kidney diseaseThe Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, 2004